49 results on '"Lupi, Cristiana"'
Search Results
2. EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: A case report
3. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
4. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
5. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer
6. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non–small cell lung cancer: Comparison with histological assessment
7. Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series
8. The BRAFV600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study
9. Correlation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases
10. Functional Characterization of the Novel T599I-VKSRdel BRAF Mutation in a Follicular Variant Papillary Thyroid Carcinoma
11. BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study
12. Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma
13. The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma
14. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens
15. ALK Rearrangement in a Large Series of Consecutive Non-Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment
16. The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness.
17. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer
18. MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations.
19. Additional file 1: Table S1: of Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer
20. P3.02b-027 Detection of EGFR Mutations in Plasma of Lung Adenocarcinoma Patients Using Real-Time PCR and Mass Spectrometry
21. EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center
22. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <italic>RAS</italic> and <italic>BRAF</italic> Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
23. Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients
24. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer
25. BRAFV600E mutation is an indipendent bad prognostic factor for the out come of patients with papillary thyroid carcinoma: a 15-year median follow-up study
26. Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
27. ALKRearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment
28. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition
29. Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer
30. KRAS and BRAF genotyping of synchronous colorectal carcinomas
31. FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment
32. BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).
33. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
34. Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts).
35. EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.
36. TheBRAFV600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study
37. P-0221 Folfoxiri Plus Bevacizumab as First-Line Treatment of Braf Mutant Metastatic Colorectal Cancer Patients
38. MicroRNA signature to predict sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC).
39. FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients.
40. Correlation between theBRAFV600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases
41. Dysregulation of secretion of CXC α-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-γ agonists
42. Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma
43. Therapeutic effect of diagnostic ultrasound on enzymatic thrombolysis
44. Therapeutic effect of diagnostic ultrasound on enzymatic thrombolysis
45. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer
46. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer
47. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.
48. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.
49. Laser capture microdissection: a tool for the molecular characterization of histologic subtypes of lung adenocarcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.